Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateJun 16, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

GALECTIN THERAPEUTICS INC. filed an 8-K on 6/16/2025 for Reg FD and exhibits.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on June 16, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.

Why It Matters

This filing indicates routine corporate reporting and potential updates on financial status or disclosures relevant to investors.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate disclosures and does not appear to contain significant new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the report filed?

The report was filed on June 16, 2025.

What is the company's former name?

The company's former name was PRO PHARMACEUTICALS INC.

Where is Galectin Therapeutics Inc. headquartered?

The company is headquartered at 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240, NORCROSS, GA 30071.

In which state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding GALECTIN THERAPEUTICS INC (GALT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing